BIGBEAR
PHARMACEUTICAL
Repotrectinib potently and selectively inhibits the abnormally activated kinase signaling pathways of ROS1 and NTRK, effectively overcomes resistance mutations to conventional targeted therapies, and exhibits favorable central nervous system penetration.
AuthenticGuaranteeFast DeliveryPrivacy Repotrectinib, a targeted drug for ROS1-positive non-small cell lung cancer, provides relief, but its potential side effects require timely detection ···【More】
Update: 10 Mar,2026Source: BigbearViews: 103
Repotrectinib has demonstrated breakthrough therapeutic efficacy against specific gene-mutant lung cancers, providing an important treatment option fo···【More】
Update: 10 Mar,2026Source: BigbearViews: 103
Repotrectinib, a novel kinase inhibitor, offers a new treatment option for certain lung cancer patients. Understanding its indications, contraindicati···【More】
Update: 10 Mar,2026Source: BigbearViews: 108
On November 16, 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved ripretinib (Augtyro) for the treatm···【More】
Update: 03 Mar,2026Source: BigbearViews: 109
Ripretinib (Augtyro) is a next-generation targeted anticancer drug developed by Bristol-Myers Squibb (BMS), offering a new precision treatment option ···【More】
Update: 03 Mar,2026Source: BigbearViews: 100
Repotrectinib is a novel, oral, small-molecule, multi-target tyrosine kinase inhibitor (TKI) primarily used to treat advanced solid tumors harboring s···【More】
Update: 03 Mar,2026Source: BigbearViews: 109
Repotrectinib, an innovative ROS1 and NTRK-targeting inhibitor, can simultaneously inhibit multiple oncogenic targets, exhibiting broad-spectrum anti-···【More】
Update: 03 Mar,2026Source: BigbearViews: 106
Repotrectinib is a new generation of targeted anticancer drug developed by Bristol-Myers Squibb (BMS), providing a new option for precision treatment ···【More】
Update: 03 Mar,2026Source: BigbearViews: 106
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
